Literature DB >> 7506279

Identification of an antigenic domain on Mycobacterium leprae protein antigen 85B, which is specifically recognized by antibodies from patients with leprosy.

E Filley1, J E Thole, G A Rook, S Nagai, M Waters, J W Drijfhout, T F Rinke de Wit, R R De Vries, C Abou-Zeid.   

Abstract

Sixty-three overlapping 15-oligomer peptides covering the 30-kDa protein antigen 85B of Mycobacterium leprae were tested by ELISA to identify epitopes recognized by human antibodies. Serum samples from patients with lepromatous leprosy (LL) reacted mainly with peptides comprising amino acid regions (AA) 206-230, 251-280, and 291-325. Sera of patients with active tuberculosis who responded to the native 30-kDa antigen did not recognize these peptides. The antibody-binding specificity to the defined B cell regions was evaluated in a blind study with 71 serum samples from patients and household contacts living in Ethiopia where leprosy is endemic. The peptide of AA 256-280 was recognized by 88% of LL patients, 15% of patients with tuberculoid leprosy, and none of the contacts. These findings suggest that there are major linear B cell epitopes on the M. leprae 30-kDa protein that are recognized by lepromin-negative LL patients, whereas lepromin-positive patients respond preferentially to conformational epitopes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7506279     DOI: 10.1093/infdis/169.1.162

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Analysis of the humoral immune response to Chlamydia outer membrane protein 2.

Authors:  P Mygind; G Christiansen; K Persson; S Birkelund
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

2.  Phage display and synthetic peptides as promising biotechnological tools for the serological diagnosis of leprosy.

Authors:  Silvana Maria Alban; Juliana Ferreira de Moura; Vanete Thomaz-Soccol; Samira Bührer Sékula; Larissa Magalhães Alvarenga; Marcelo Távora Mira; Carlos Chávez Olortegui; João Carlos Minozzo
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.